[Micelle carrier system in clinical trial].
The problems of cytotoxic agents have been attributed to their low therapeutic indices and limited efficacy due to the non selective nature of their molecular targets and their inability to accumulate selectively in cancer tissue. Passive targeting is based on the so-called enhanced permeability and retention (EPR) effect. To use the EPR effect to full advantage, several techniques have been developed, namely, modification of the structures of drugs and development of drug carriers. In this review article, the results of preclinical and clinical studies of doxorubicin-incorporating immunoliposome, MCC-465 and micelle -forming polymeric drugs such as doxorubicin-incorporating micelle, NK911 and taxol-incorpolating micelle, NK105.
Matsumura
Yasuhiro
Y
Investigative Treatment Division, National Cancer Center Research Institute East.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008081:Liposomes; D008823:Micelles; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010539:Permeability; D011092:Polyethylene Glycols / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008081:Liposomes; D008823:Micelles; C500671:NK105; C438847:NK911; D010455:Peptides; D011092:Polyethylene Glycols; D004317:Doxorubicin; D017239:Paclitaxel